Description
First part- Due Thursday During this week you were provided with information regarding classifications of drugs and brain function. For your original thread, find an educational video on one drug classification you signed up for on the Wiki and post the video link; videos can be found on YouTube. You may refer back to both books and supplemental reading for drug classifications. I signed up for narcotics. Second part- Due Sunday Respond to another student’s main post by posting two different videos that discusses a specific drug that fall under two separate drug classification of your choice. For example, if you are responding to the hallucinogen classification you would find a educational video on ecstasy or LSD. The video should discuss what the drug is and the effect it has on the body. The video could also be personal testimonials from individuals sharing the impact the drug has had in their lives. for these 2 videos could be steroids, depressants, inhalants, or cannabis. Once you post the video as a respond to your classmate, answer the following 3 questions: What did you learn about the drug classification?What surprised you the most about the information you found in the video?How would you use this information to educate clients on substance use? https://counseling.education/counseling/substance_use/conceptualizing.html
Unformatted Attachment Preview
Drugs of Abuse
A DEA RESOURCE GUIDE
PRODUCED AND PUBLISHED BY
Drug Enforcement Administration • U.S. Department of Justice
WWW.DEA.GOV
Contents
Welcome …………………………………………………………….. 7
VI. Depressants ………………………………………………….. 56
I. Controlled Substances Act …………………………………… 8
Barbiturates ………………………………………………………………58
Drug Scheduling ……………………………………………………….15
Benzodiazepines ……………………………………………………….59
Schedule I …………………………………………………………………15
GHB………………………………………………………………………….60
Schedule II ………………………………………………………………..22
Rohypnol…………………………………………………………………..62
Schedule III ……………………………………………………………….24
VII. Hallucinogens ………………………………………………. 64
Schedule IV……………………………………………………………….27
Ecstasy/MDMA …………………………………………………………66
Schedule V………………………………………………………………..29
Ketamine ………………………………………………………………….68
Federal Trafficking Penalties ………………………………………30
LSD …………………………………………………………………………..70
Federal Trafficking Penalties—Marijuana ……………………31
Peyote & Mescaline …………………………………………………..71
II. U.S. Chemical Control ……………………………………… 32
Psilocybin ………………………………………………………………….72
Listed Chemicals Chart ……………………………………………..34
VIII. Marijuana/Cannabis ……………………………………… 74
III. Introduction to Drug Classes……………………………. 36
Marijuana Concentrates …………………………………………….76
IV. Narcotics ………………………………………………………. 38
IX. Steroids ……………………………………………………….. 78
Fentanyl ……………………………………………………………………40
X. Inhalants ……………………………………………………….. 80
Heroin ………………………………………………………………………42
XI. Drugs of Concern ………………………………………….. 82
Hydromorphone ……………………………………………………….43
DXM …………………………………………………………………………82
Methadone ……………………………………………………………….44
Kratom ……………………………………………………………………..84
Morphine ………………………………………………………………….45
Salvia Divinorum ……………………………………………………….85
Opium ………………………………………………………………………46
XII. Designer Drugs …………………………………………….. 86
Oxycodone ……………………………………………………………….47
Bath Salts or Designer Cathinones …………………………….86
V. Stimulants ……………………………………………………… 48
K2 /Spice …………………………………………………………………..88
Amphetamines ………………………………………………………….50
Synthetic Opioids ……………………………………………………..90
Cocaine…………………………………………………………………….51
XIII. Resources……………………………………………………. 92
Khat ………………………………………………………………………….53
Methamphetamine ……………………………………………………54
DRUGS OF ABUSE I 2017 EDITION: A DEA Resource Guide
5
Welcome
TO THE LATEST EDITION OF
DRUGS OF ABUSE
Education plays a critical role in preventing substance abuse.
Drugs of Abuse, A DEA Resource Guide, is designed to be a
reliable resource on the most commonly abused and misused
drugs in the United States. This comprehensive guide provides
important information about the harms and consequences of
drug use by describing a drug’s effects on the body and mind,
overdose potential, origin, legal status, and other key facts.
Drugs of Abuse also offers a list of additional drug education
and prevention resources, including the DEA websites:
www.DEA.gov; www.JustThinkTwice.com, aimed at teenagers;
www.GetSmartAboutDrugs.com, designed for parents, educators, and caregivers; and www.operationprevention.com.
DRUGS OF ABUSE I 2017 EDITION: A DEA Resource Guide
7
I. Controlled Substances Act
CONTROLLING DRUGS OR OTHER
SUBSTANCES THROUGH FORMAL
SCHEDULING
the Assistant Secretary for Health of HHS.
The Controlled Substances Act (CSA) places all substances
scientific evaluation regarding the drug or other substance, a
which were in some manner regulated under existing federal
recommendation as to whether the drug should be controlled,
law into one of five schedules. This placement is based upon
and in what schedule it should be placed.
the substance’s medical use, potential for abuse, and safety or
The medical and scientific evaluations are binding on the DEA
dependence liability. The Act also provides a mechanism for
with respect to scientific and medical matters and form a part
substances to be controlled (added to or transferred between
of the scheduling decision.
schedules) or decontrolled (removed from control). The
procedure for these actions is found in Section 201 of the Act
(21U.S.C. §811).
the information and transmits back to the DEA: a medical and
Once the DEA has received the scientific and medical evaluation from HHS, the Administrator will evaluate all available
data and make a final decision whether to propose that a drug
Proceedings to add, delete, or change the schedule of a drug
or other substance should be removed or controlled and into
or other substance may be initiated by the Drug Enforce-
which schedule it should be placed.
ment Administration (DEA), the Department of Health and
Human Services (HHS), or by petition from any interested
party, including:
If a drug does not have a potential for abuse, it cannot be
controlled. Although the term “potential for abuse” is not
defined in the CSA, there is much discussion of the term in the
• The manufacturer of a drug
legislative history of the Act. The following items are indicators
• A medical society or association
that a drug or other substance has a potential for abuse:
• A pharmacy association
(1) There is evidence that individuals are taking the drug or
• A public interest group concerned with drug abuse
• A state or local government agency
• An individual citizen
other substance in amounts sufficient to create a hazard
to their health or to the safety of other individuals or to
the community.
(2) There is significant diversion of the drug or other sub-
When a petition is received by the DEA, the agency begins its
stance from legitimate drug channels.
own investigation of the drug. The DEA also may begin an
(3) Individuals are taking the drug or other substance on their
investigation of a drug at any time based upon information
received from law enforcement laboratories, state and local
law enforcement and regulatory agencies, or other sources
of information.
Once the DEA has collected the necessary data, the DEA
Administrator, by authority of the Attorney General, requests
from HHS a scientific and medical evaluation and recommendation as to whether the drug or other substance should
be controlled or removed from control. This request is sent to
8
The Assistant Secretary, by authority of the Secretary, compiles
DRUGS OF ABUSE I A DEA Resource Guide: 2017 EDITION
own initiative rather than on the basis of medical advice from
a practitioner.
(4) The drug is a new drug so related in its action to a drug or
other substance already listed as having a potential for abuse
to make it likely that the drug will have the same potential for
abuse as such drugs, thus making it reasonable to assume
that there may be significant diversions from legitimate channels, significant use contrary to or without medical advice, or
that it has a substantial capability of creating hazards to the
health of the user or to the safety of the community. Of course,
by the CSA. They are as follows:
evidence of actual abuse of a substance is indicative that a drug
has a potential for abuse.
Schedule I
In determining into which schedule a drug or other substance
• The drug or other substance has a high potential for abuse.
should be placed, or whether a substance should be decontrolled
• The drug or other substance has no currently accepted
or rescheduled, certain factors are required to be considered.
These factors are listed in Section 201 (c), [21 U.S.C. § 811 (c)] of
the CSA as follows:
(1)The drug’s actual or relative potential for abuse.
(2)Scientific evidence of the drug’s pharmacological effect, if known.
The state of knowledge with respect to the effects of a specific
medical use in treatment in the United States.
• There is a lack of accepted safety for use of the drug or other
substance under medical supervision.
• Examples of Schedule I substances include heroin, gamma
hydroxybutyric acid (GHB), lysergic acid diethylamide (LSD),
marijuana, and methaqualone.
drug is, of course, a major consideration. For example, it is vital
Schedule II
to know whether or not a drug has a hallucinogenic effect if it is
• The drug or other substance has a high potential for abuse.
to be controlled due to that effect.
• The drug or other substance has a currently accepted medical
The best available knowledge of the pharmacological properties
of a drug should be considered.
(3)The state of current scientific knowledge regarding the substance.
Criteria (2) and (3) are closely related. However, (2) is primarily
concerned with pharmacological effects and (3) deals with all
scientific knowledge with respect to the substance.
(4)Its history and current pattern of abuse. To determine whether
use in treatment in the United States or a currently accepted
medical use with severe restrictions.
• Abuse of the drug or other substance may lead to severe
psychological or physical dependence.
• Examples of Schedule II substances include morphine,
phencyclidine (PCP), cocaine, methadone, hydrocodone,
fentanyl, and methamphetamine.
or not a drug should be controlled, it is important to know the
Schedule III
pattern of abuse of that substance.
• The drug or other substance has less potential for abuse than
(5)The scope, duration, and significance of abuse. In evaluating
existing abuse, the DEA Administrator must know not only the
pattern of abuse, but also whether the abuse is widespread.
(6)What, if any, risk there is to the public health. If a drug creates
dangers to the public health, in addition to or because of its
the drugs or other substances in Schedules I and II.
• The drug or other substance has a currently accepted medical
use in treatment in the United States.
• Abuse of the drug or other substance may lead to moderate or
low physical dependence or high psychological dependence.
• Anabolic steroids, codeine products with aspirin or
abuse potential, then these dangers must also be considered by
Tylenol, and some barbiturates are examples of Schedule
the Administrator.
III substances.
(7)The drug’s psychic or physiological dependence liability. There
must be an assessment of the extent to which a drug is physically addictive or psychologically habit forming.
(8)Whether the substance is an immediate precursor of a substance
already controlled. The CSA allows inclusion of immediate
precursors on this basis alone into the appropriate schedule and
Schedule IV
• The drug or other substance has a low potential for abuse
relative to the drugs or other substances in Schedule III.
• The drug or other substance has a currently accepted medical
use in treatment in the United States.
• Abuse of the drug or other substance may lead to limited
thus safeguards against possibilities of clandestine manufacture.
physical dependence or psychological dependence relative to
After considering the above listed factors, the Administrator
the drugs or other substances in Schedule III.
must make specific findings concerning the drug or other
substance. This will determine into which schedule the drug or
• Examples of drugs included in Schedule IV are alprazolam,
clonazepam, and diazepam.
other substance will be placed. These schedules are established
DRUGS OF ABUSE I 2017EDITION: A DEA Resource Guide
9
Schedule V
Emergency or Temporary Scheduling
» The drug or other substance has a low potential for abuse
The CSA was amended by the Comprehensive Crime Control
relative to the drugs or other substances in Schedule IV.
Act of 1984. This Act included a provision which allows the DEA
» The drug or other substance has a currently accepted medical
Administrator to place a substance, on a temporary basis, into
use in treatment in the United States.
» Abuse of the drug or other substances may lead to limited
physical dependence or psychological dependence relative to
the drugs or other substances in Schedule IV.
» Cough medicines with codeine are examples of
Schedule V drugs.
Schedule I, when necessary, to avoid an imminent hazard to
public safety.
This emergency scheduling authority permits the scheduling of
a substance which is not currently controlled, is being abused,
and is a risk to public health while the formal rulemaking
procedures described in the CSA are being conducted. This
When the DEA Administrator has determined that a drug
emergency scheduling applies only to substances with no
or other substance should be controlled, decontrolled, or
accepted medical use.
rescheduled, a proposal to take action is published in the Federal
Register. The proposal invites all interested persons to file
comments with the DEA and may also request a hearing with the
DEA. If no hearing is requested, the DEA will evaluate all comments received and publish a final order in the Federal Register,
controlling the drug as proposed or with modifications based
upon the written comments filed. This order will set the effective
dates for imposing the various requirements of the CSA.
A temporary scheduling order may be issued for two years with
a possible extension of up to one year if formal scheduling
procedures have been initiated. The notice of intent and order
are published in the Federal Register, as are the proposals and
orders for formal scheduling. [21 U.S.C. § 811 (h)]
Controlled Substance analogues
Controlled substance analogues are substances that are not
If a hearing is requested, the DEA will enter into discussions
formally controlled substances, but may be found in illicit
with the party or parties requesting a hearing in an attempt to
trafficking. They are structurally or pharmacologically similar to
narrow the issue for litigation. If necessary, a hearing will then
Schedule I or II controlled substances and have no legitimate
be held before an Administrative Law Judge. The judge will
medical use. A substance that meets the definition of a con-
take evidence on factual issues and hear arguments on legal
trolled substance analogue and is intended for human consump-
questions regarding the control of the drug. Depending on the
tion may be treated under the CSA as if it were a controlled
scope and complexity of the issues, the hearing may be brief or
substance in Schedule I. [21 U.S.C. § 802(32), 21 U.S.C. § 813]
quite extensive. The Administrative Law Judge, at the close of the
hearing, prepares findings of fact and conclusions of law and a
International treaty obligations
recommended decision that is submitted to the DEA Administra-
United States treaty obligations may require that a drug or other
tor. The DEA Administrator will review these documents, as well
substance be controlled under the CSA, or rescheduled if existing
as the underlying material, and prepare his/her own findings
controls are less stringent than those required by a treaty. The
of fact and conclusions of law (which may or may not be the
procedures for these scheduling actions are found in Section 201
same as those drafted by the Administrative Law Judge). The
(d)of the Act. [21 U.S.C. § 811 (d)]
DEA Administrator then publishes a final order in the Federal
The United States is a party to the Single Convention on Narcotic
Register either scheduling the drug or other substance or
Drugs of 1961, which was designed to establish effective control
declining to do so.
over international and domestic traffic in narcotics, coca leaf,
Once the final order is published in the Federal Register, inter-
cocaine, and cannabis. A second treaty, the Convention on
ested parties have 30 days to appeal to a U.S. Court of Appeals
Psychotropic Substances of 1971, which entered into force
to challenge the order. Findings of fact by the Administrator
in 1976 and was ratified by Congress in 1980, is designed to
are deemed conclusive if supported by “substantial evidence.”
establish comparable control over stimulants, depressants,
The order imposing controls is not stayed during the appeal,
and hallucinogens.
however, unless so ordered by the Court.
10
DRUGS OF ABUSE I A DEA Resource Guide: 2017 EDITION
REGULATION
The CSA creates a closed system of distribution for controlled substances.
The cornerstone of this system is the registration of all those
authorized by DEA to handle controlled substances. All individuals and firms that are registered are required to maintain
complete and accurate inventories, and records of all transactions involving controlled substances, as well as security for the
storage of controlled substances.
Registration
Any person who handles or intends to handle controlled
substances must obtain a registration issued by DEA. A unique
number is assigned to each legitimate handler of controlled
drugs such as importer, exporter, manufacturer, distributor,
hospital, pharmacy, practitioner, and researcher.
Distribution
Maintaining records is required for distribution of a controlled
substance from one manufacturer to another, from manufacturer
to distributor, and from distributor to dispenser. In the case of
Schedule I and II drugs, the supplier must first receive a special
order from the customer. This order form (DEA Form 222) is
issued by DEA only to persons who are properly registered to
handle Schedule I and II controlled substances.
The form is preprinted with the name and address of the
customer. The drugs must be shipped to this name and address.
The use of this form is a special reinforcement of the registration
requirement; it ensures that only authorized individuals may
obtain Schedule I and II drugs.
Controlled Substance Ordering System (CSOS) –
Electronic Order Forms
Any registrant permitted to order Schedule II controlled
This number must be made available to the supplier by the
substances may do so electronically via the DEA Controlled
customer prior to the purchase of a controlled substance, and
Substance Ordering System (CSOS). The use of electronic orders
its validity can be verified online through the Diversion Control
is optional; registrants may continue to issue orders on a paper
Division website at www.DEAdiversion.usdoj.gov. Thus, the
DEA Form 222. CSOS allows for secure electronic transmission
opportunity for unauthorized transactions is greatly diminished.
of controlled substance orders without the supporting paper
Recordkeeping and Reporting
The CSA requires that complete and accurate records be kept of
all quantities of controlled substances manufactured, imported,
exported, received, delivered, distributed, dispensed, or otherwise disposed. Each substance must be physically inventoried
every two years. Some limited exceptions to the recordkeeping
requirements apply to certain categories of registrants.
DEA Form 222. The adoption of the CSOS standards is the only
allowance for the electronic transmission of Schedule II controlled substance orders between controlled substance manufacturers, distributors, pharmacies, and other DEA authorized
entities. CSOS uses Public Key Infrastructure (PKI) technology,
which requires CSOS users to obtain a CSOS digital certificate
for electronic ordering. The electronic orders must be signed
using a digital signature issued by a Certification Authority (CA)
From these records it is possible to trace the flow of any drug
operated by DEA.
from the time it is first imported or manufactured, through the
Digital certificates can be obtained only by registrants and indi-
distribution level, to the pharmacy or hospital that dispensed it,
and then to the actual patient who received the drug. The mere
existence of this requirement is sufficient to discourage many
forms of diversion. It actually serves large drug corporations
as an internal check to uncover diversion, such as pilferage
by employees.
viduals granted power of attorney by registrants to sign orders.
A registrant must appoint a CSOS coordinator who will serve as
that registrant’s recognized agent regarding issues pertaining
to issuance of, revocation of, and changes to, digital certificates
issued under that registrant’s DEA registration. A CSOS digital
certificate will be valid until the DEA registration under which it is
There is one distinction between scheduled items for record
issued expires or until the CSOS CA is notified that the certificate
keeping requirements. Records for Schedule I and II drugs
should be revoked. Certificates will be revoked if the certificate
must be kept separate from all other records maintained by the
holder is no longer authorized to sign Schedule II orders for the
registrant. Records for Schedule III, IV, and V substances must
registrant, if the information on which the certificate is based
be kept in a “readily retrievable” form, or maintained separately
changes, or if the digital certificate used to sign electronic orders
from all other records.
has been compromised, stolen, or lost.
DRUGS OF ABUSE I A DEA Resource Guide: 2017 EDITION
11
One benefit of using the CSOS system is that participants
tration, by prescription, or by dispensing.
who are registered in other schedules in addition to schedule
Records must be maintained by the practitioner of all dispensing
II can then use this same system to also order those other
of controlled substances and of certain administrations.
controlled substances.
Another benefit of the DEA Form 222 is the special monitoring
it permits. The form is issued in triplicate: the customer keeps
one copy; two copies go to the supplier, who, after filling the
order, keeps a copy and forwards the third copy to the nearest DEA office.
For drugs in Schedules III, IV, and V, no order form is necessary,
but both the supplier and the purchaser must still maintain
records of all transactions involving these controlled substances
and those records must contain specific information required by
DEA regulation.
The supplier in each case, however, is under an obligation to
verify the authenticity of the customer. The supplier is held fully
accountable for any drugs that are shipped to a purchaser who
does not have a valid registration. Manufacturers must submit
periodic reports of the Schedule I and II controlled substances
they produce in bulk and dosage forms.
They also report the manufactured quantity and form of each
narcotic substance listed in Schedule III. Distributors of
controlled substances must report the quantity and form of all
their transactions of controlled drugs listed in Schedules I and
II, narcotics listed in Schedule III, and GHB. Both manufacturers
and distributors are required to provide reports of their annual
inventories of these controlled substances. This data is entered
into a system called the Automated Reports and Consolidated
Orders System (ARCOS). It enables the DEA to monitor the
distribution of controlled substances throughout the country, and
to identify retail level registrants that receive unusual quantities
of controlled substances.
Dispensing to Patients
The dispensing of a controlled substance is the delivery by a
12
The CSA does not require the practitioner to maintain copies
of prescriptions unless such substances are prescribed in the
course of maintenance or detoxification treatment of an individual. Certain states require the use of multiple-copy prescriptions
for Schedule II and other specified controlled substances.
The determination to place drugs on prescription is within the
jurisdiction of the FDA. Unlike other prescription drugs, however,
controlled substances are subject to additional restrictions.
Schedule II prescription orders must be written and signed by
the practitioner; they may not be telephoned into the pharmacy
except in an emergency. In addition, a prescription for a Schedule
II drug may not be refilled. For Schedule III and IV drugs, the
prescription order may be either written or oral (that is, by
telephone to the pharmacy). In addition, the patient may (if
authorized by the practitioner) have the prescription refilled up
to five times and at any time within six months from the date the
prescription was issued.
Schedule V includes some prescription drugs and many narcotic
preparations, including antitussives and antidiarrheals. Even
here, however, the law imposes restrictions beyond those
normally required for the over-the-counter sales; for example, the
patient must be at least 18 years of age, must offer some form of
identification, and have his or her name entered into a special log
maintained by the pharmacist as part of a special record.
Electronic Prescriptions
On March 31, 2010, DEA published in the Federal Register the
Electronic Prescriptions for Controlled Substances interim final rule
which became effective June 1, 2010. The rule provides practitioners
with the option of writing prescriptions for controlled substances
electronically and also permits pharmacies to receive, dispense, and
practitioner of the controlled substance to the ultimate user, who
archive these electronic prescriptions.
may be a patient or research subject. Special control mechanisms
Persons who wish to dispense controlled substances using
operate here as well. Schedule I drugs are those that have no
electronic prescriptions must select software that meets the
currently accepted medical use in the United States; therefore,
requirements of this rule. As of June 1, 2010, only those electronic
they may be used in the United States only in research situations.
applications that comply with all of DEA’s requirements as set forth
They generally are supplied by only a limited number of firms
in 21 C.F.R. §1311 may be used to electronically create, transmit,
to properly registered and qualified researchers. Controlled
receive/archive controlled substances prescriptions, and dispense
substances may be dispensed by a practitioner by direct adminis-
controlled substances based on those prescriptions.
DRUGS OF ABUSE I A DEA Resource Guide: 2017 EDITION
Ryan Haight Online Pharmacy Consumer Protection
Act of 2008
must store controlled substances in specially constructed vaults
On October 15, 2008, the President signed into law the Ryan
age areas. Lesser physical security requirements apply to retail
Haight Online Pharmacy Consumer Protection Act of 2008, often
level registrants such as hospitals and pharmacies. All regis-
referred to as the Ryan Haight Act. This law amends the CSA
trants are required to make every effort to ensure that controlled
by adding a series of new regulatory requirements and criminal
substances in their possession are not diverted into the illicit
provisions designed to combat the proliferation of so-called
market. This requires operational as well as physical security. For
“rogue Internet sites” that unlawfully dispense controlled sub-
example, registrants are responsible for ensuring that controlled
stances by means of the Internet. The Ryan Haight Act applies
substances are distributed only to other registrants that are
to all controlled substances in all schedules. An online pharmacy
authorized to receive them, or to legitimate patients.
is a person, entity, or Internet site, whether in the United States
or highly rated safes, and maintain electronic security for all stor-
or abroad, that knowingly or intentionally delivers, distributes,
Controlled Substance Theft or Significant Loss
or dispenses, or offers or attempts to deliver, distribute, or
Should a theft or significant loss of any controlled substance
dispense, a controlled substance by means of the Internet.
occur, a registrant must implement the following procedures
This law became effective April 13, 2009. As of that date, it is
within one business day of the discovery of the theft or loss.
illegal under federal law to deliver, distribute, or dispense a
A. Notify DEA and Local Police
controlled substance by means of the Internet unless the online
The theft of controlled substances from a registrant is a criminal
pharmacy holds a modification of DEA registration authorizing it
act and a source of diversion that requires notification to DEA.
to operate as an online pharmacy.
A registrant must notify in writing the local DEA Diversion
Quotas
DEA limits the quantity of Schedule I and II controlled
substances and specific List I chemicals (pseudoephedrine,
ephedrine, and phenylpropanolamine) that may be produced
in the United States in any given calendar year for legitimate
medical, scientific and research needs, inventory, and lawful
exports. By utilizing available data on sales and inventories of
these controlled substances, and taking into account estimates
of drug usage provided by the FDA, the DEA establishes annual
aggregate production quotas for Schedule I and II controlled
substances and the List I chemicals pseudoephedrine,
ephedrine, and phenylpropanolamine.
The aggregate production quotas and the assessment of annual
needs are allocated among the various manufacturers who are
registered to manufacture the specific substance or listed chemical. DEA also allocates the amount of bulk material that may be
procured by those DEA registered manufacturers that prepare
the substances into dosage units.
Field Office within one business day of discovery of a theft or
significant loss of a controlled substance. Although not specifically required by federal law or regulations, the registrant should
also notify local law enforcement and state regulatory agencies.
Prompt notification to enforcement agencies will allow them
to investigate the incident and prosecute those responsible
for the diversion. If there is a question as to whether a theft
has occurred or a loss is significant, a registrant should err on
the side of caution and report it to DEA and local law enforcement authorities.
DEA must be notified directly. This requirement is not satisfied
by reporting the theft or significant loss in any other manner.
For example, a corporation which owns or operates multiple
registered sites and wishes to channel all notifications through
corporate management or any other internal department
responsible for security, must still provide notice directly to DEA
in writing within one business day upon discovery and keep a
copy of that notice for its records. The notice must be signed by
an authorized individual of the registrant.
Security
B. Complete DEA Form 106
DEA registrants are required by regulation to maintain certain
A registrant must also complete a DEA Form 106 (Report of
security for the storage and distribution of controlled substances.
Theft or Loss of Controlled Substances) which can be found
Manufacturers and distributors of Schedule I and II substances
online at www.DEAdiversion.usdoj.gov under the Quick Links
DRUGS OF ABUSE I A DEA Resource Guide: 2017 EDITION
13
section. The DEA Form 106 is used to document the actual
User Accountability also targets businesses interested in doing
circumstances of the theft or significant loss and the quantities
business with the federal government. This program requires
of controlled substances involved. A paper versio
